You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石药集团(01093.HK)附属开发药品获一致性评价
阿思达克 12-11 16:47

石药集团(01093.HK)公布,附属石药集团欧意药业开发的「布洛芬片(0.1g)」已获中国药监局批准通过仿制药质量和疗效一致性评价。通过一致性评价,表明该产品质量和疗效与原研药品一致,为患者提供优质优价的用药选择。布洛芬片为公司非处方药品的重点产品之一,是国内首家通过一致性评价的同类产品。

公司并表示,布洛芬片为解热镇痛类非处方药品,用於缓解轻至中度疼痛如头痛、关节痛、偏头痛、牙痛、肌肉痛、神经痛、痛经,也用於普通感冒或流行性感冒引起的发热。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account